SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Atara Biotherapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

046513206

(CUSIP Number)

Joshua Garcia Redmile Group, LLC, One Letterman Drive Bldg D, Ste D3-300 San Francisco, CA, 94129 (415) 489-9980

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

11/12/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 046513206

1	Name of reporting person	
	Redmile Group, LLC	
2	Check the appropriate box if a member of a Group (See Instructions)	
	□ (a) □ (b)	
3	SEC use only	
4	Source of funds (See Instructions)	
	00	

5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	
6	Citizenship or place of organization DELAWARE	
Number	7	Sole Voting Power 0.00
of Shares Benefici ally Owned	8	Shared Voting Power 751,223.00
by Each Reporti ng Person	9	Sole Dispositive Power 0.00
With:	10	Shared Dispositive Power 751,223.00
11	Aggregate amount beneficially owned by each reporting person 751,223.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)	
13	Percent of class represented by amount in Row (11) 9.9 %	
14	Type of Reporting Person (See Instructions) IA, OO	

Redmile Group, LLC's beneficial ownership of the Issuer's common stock ("Common Stock") is comprised of 441,701 shares of Common Stock owned by certain private investment vehicles managed by Redmile Group, LLC (the "Redmile Funds"), including RedCo I, L.P. ("RedCo I"), Redmile Biopharma Investments II, L.P. ("RBI II") and Redmile Strategic Long Only Trading Sub, Ltd. ("Redmile Long Only"). Subject to the Beneficial Ownership Blocker (as defined below), Redmile Group, LLC may a loo be deemed to beneficially own 3,412,843 shares of Common Stock issuable upon exercise of certain pre-funded warrants to purchase Common Stock (the "Warrants") held directly by the Redmile Funds. Pursuant to the terms of the Warrants, the I ssuer may not effect any exercise of the Warrants, and a holder of a Warrants does not have the right to exercise the Warrant ts held by such holder, to the extent that after giving effect to such issuance after exercise, the holder (together with the holde r's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates), would beneficial ly own in excess of 9.99% (the "Beneficial Ownership Limitation") of the number of shares of Common Stock outstanding im mediately after giving effect to the issuance of shares of Common Stock issued upon exercise of the Warrant (the "Beneficial Ownership Blocker"). The Beneficial Ownership Limitation may be changed at a holder's election upon 61 days' notice to the Issuer. The 751,223 shares of Common Stock reported as beneficially owned by Redmile Group, LLC in this Schedule 13D represent 9.99% of the outstanding shares of Common Stock (calculated in accordance with the footnote below) and include s 309,522 shares of Common Stock that could be issued upon exercise of certain of the Warrants directly held by the Redmile Funds. The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of the Redmile Funds. The reported securities may also be deemed beneficially owned by I

Percentage based on the sum of: (i) 7,210,235 shares of Common Stock outstanding as of November 6, 2025, as reported by the Issuer in its Form 10-Q for the quarterly period ended September 30, 2025 filed with the Securities and Exchange Commi ssion (the "SEC") on November 11, 2025 (the "Form 10-Q"), plus (ii) 309,522 shares of Common Stock issuable upon exercise of the Warrants directly held by the Redmile Funds, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued upon exercise of those Warrants.

046513206

1	Name of reporting person
	Jeremy C. Green

2 (a)		e appropriate box if a member of a Group (See Instructions)		
	(b)			
3	SEC use	SEC use only		
4	Source of funds (See Instructions)			
	00			
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)			
6	Citizensh	ip or place of organization		
	UNITED K	INGDOM		
	_	Sole Voting Power		
	7	0.00		
Number of		Shared Voting Power		
Shares Benefici	8	751,223.00		
ally Owned	9	Sole Dispositive Power		
by Each Reporti	3	0.00		
ng Person With:	10	Shared Dispositive Power		
WILII.		751,223.00		
44	Aggregate amount beneficially owned by each reporting person			
11	751,223.00			
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)			
12				
13	Percent of class represented by amount in Row (11)			
13	9.9 %			
14	Type of Reporting Person (See Instructions)			
14	IN, HC			

Jeremy C. Green's beneficial ownership of Common Stock is comprised of 441,701 shares of Common Stock owned by the R edmile Funds, including RedCo I, RBI II and Redmile Long Only. Subject to the Beneficial Ownership Blocker, Mr. Green may also be deemed to beneficially own 3,412,843 shares of Common Stock issuable upon exercise of the Warrants held directly by the Redmile Funds. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of the Warrant, and a holder of a Warrant does not have the right to exercise the Warrant held by such holder, to the extent that the Beneficial Ownership Blocker applies. The 751,223 shares of Common Stock reported as beneficially owned by Mr. Green in this Schedule 13D represent 9.99% of the outstanding shares of Common Stock (calculated in accordance with the footnote below) and includes 309,522 shares of Common Stock that could be issued upon exercise of certain of the Warrants directly held by the Redmile Funds under the Beneficial Ownership Blocker. The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of the Redmile Funds. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

Percentage based on the sum of: (i) 7,210,235 shares of Common Stock outstanding as of November 6, 2025, as reported by the Issuer in its Form 10-Q, plus (ii) 309,522 shares of Common Stock issuable upon exercise of the Warrants directly held by the Redmile Funds, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issue dupon exercise of those Warrants.

1	Name of reporting person			
	RedCo I, L.P.			
	Check the appropriate box if a member of a Group (See Instructions)			
2	(a) (b)			
3	SEC use of	only		
_	Source of funds (See Instructions)			
4	WC			
_	Check if d	disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)		
5				
•	Citizenshi	Citizenship or place of organization		
6	DELAWAF	DELAWARE		
		Sole Voting Power		
	7	0.00		
Number		Shared Voting Power		
of Shares	8	347,442.00		
Benefici ally		Sole Dispositive Power		
Owned by Each Reporti	9	0.00		
ng Person	10	Shared Dispositive Power		
With:		347,442.00		
44	Aggregate amount beneficially owned by each reporting person			
11	347,442.00			
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)			
40	Percent of class represented by amount in Row (11)			
13	4.7 %			
14	Type of Reporting Person (See Instructions)			
14	PN			

The shares of Common Stock reported as beneficially owned by RedCo I in this Schedule 13D represent the 191,226 shares of Common Stock held directly by RedCo I and the 156,216 shares of Common Stock that could be issued to RedCo I upon e xercise of the Warrants directly held by RedCo I.

Percentage based on the sum of: (i) 7,210,235 shares of Common Stock outstanding as of November 6, 2025, as reported by the Issuer in its Form 10-Q, plus (ii) 156,216 shares of Common Stock issuable upon exercise of the Warrants directly held b y RedCo I.

CUSIP No. 046513206

1	Name of reporting person
	Redmile Biopharma Investments II, L.P.

2	Check the	e appropriate box if a member of a Group (See Instructions)	
3	SEC use only		
4	Source of funds (See Instructions) WC		
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)		
6	Citizenship or place of organization DELAWARE		
Number of	7	Sole Voting Power 0.00	
Shares Benefici ally Owned	8	Shared Voting Power 452,153.00	
by Each Reporti ng Person	9	Sole Dispositive Power 0.00	
With:	10	Shared Dispositive Power 452,153.00	
11	Aggregate amount beneficially owned by each reporting person 452,153.00		
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)		
13	Percent of class represented by amount in Row (11) 6.0 %		
14	Type of Reporting Person (See Instructions) PN		

RBI II's beneficial ownership of Common Stock is comprised of 142,631 shares of Common Stock directly held by RBI II. Subject to the Beneficial Ownership Blocker, RBI II may also be deemed to beneficially own 2,054,155 shares of Common Stock i ssuable upon exercise of the Warrants directly held by RBI II. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of any Warrant, and a holder of a Warrant does not have the right to exercise any portion of the Warrant held by such holder, if the Beneficial Ownership Blocker applies. The shares of Common Stock reported as beneficially owned by RBI II in this Schedule 13D represent the shares of Common Stock held directly by RBI II and the 309,522 shares of Common Stock that could be issued to RBI II upon exercise of certain of the Warrants directly held by RBI II under the Beneficial Ownership Blocker.

Percentage based on the sum of: (i) 7,210,235 shares of Common Stock outstanding as of November 6, 2025, as reported by the Issuer in its Form 10-Q, plus (ii) 309,522 shares of Common Stock issuable upon exercise of the Warrants directly held by RBI II, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued upon exercise of those Warrants.

CUSIP No. 046513206

1	Name of reporting person
	Redmile Strategic Long Only Trading Sub, Ltd.
	Treating Strategic Long Striy Trading Sub, Etc.

2	Check the appropriate box if a member of a Group (See Instructions) (a) (b)		
3	SEC use only		
4	Source of funds (See Instructions) WC		
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)		
6	Citizenship or place of organization CAYMAN ISLANDS		
Number of	7	Sole Voting Power 0.00	
Shares Benefici ally Owned	8	Shared Voting Power 376,377.00	
by Each Reporti ng Person	9	Sole Dispositive Power 0.00	
With:	10	Shared Dispositive Power 376,377.00	
11	Aggregate amount beneficially owned by each reporting person 376,377.00		
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)		
13	Percent of class represented by amount in Row (11) 5.0 %		
14	Type of Reporting Person (See Instructions)		

Redmile Long Only's beneficial ownership of Common Stock is comprised of 66,855 shares of Common Stock directly held by Redmile Long Only. Subject to the Beneficial Ownership Blocker, Redmile Long Only may also be deemed to beneficially ow n 827,581 shares of Common Stock issuable upon exercise of the Warrants directly held by Redmile Long Only. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of any Warrant, and a holder of a Warrant does not have the right to exercise any portion of the Warrant held by such holder, if the Beneficial Ownership Blocker applies. The shares of Common Stock reported as beneficially owned by Redmile Long Only in this Schedule 13D represent the shares of Common Stock held directly by Redmile Long Only and the 309,522 shares of Common Stock that could be issued to Redmile Long Only upon exercise of certain of the Warrants directly held by Redmile Long Only under the Beneficial Ownership Blocker.

Percentage based on the sum of: (i) 7,210,235 shares of Common Stock outstanding as of November 6, 2025, as reported by the Issuer in its Form 10-Q, plus (ii) 309,522 shares of Common Stock issuable upon exercise of the Warrants directly held by Redmile Long Only, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issue dupon exercise of those Warrants.

SCHEDULE 13D

Item 1. Security and Issuer

(a) Title of Class of Securities:

Common Stock, par value \$0.0001 per share

(b) Name of Issuer:

Atara Biotherapeutics, Inc.

(c) Address of Issuer's Principal Executive Offices:

1280 Rancho Conejo Blvd, Thousand Oaks, CALIFORNIA, 91320.

Item 2. Identity and Background

(a) This Amendment No. 1 to Schedule 13D amends and supplements the Schedule 13D filed with the SEC on May 23, 2025 (the "Pri or Schedule 13D") to reflect the addition of Redmile Strategic Long Only Trading Sub, Ltd. ("Redmile Long Only").

Redmile Long Only became a reporting person solely as a result of an increase in the aggregate number of the Issuer's outstanding Common Stock, which increased the number of shares of Common Stock issuable to Redmile Long Only upon exercise of certa in pre-funded warrants to purchase Common Stock under the beneficial ownership limitation. The Reporting Persons have not engaged in any transactions since the Prior Schedule 13D. Capitalized terms used but not defined in this Amendment No. 1 shall have the meanings set forth in the Prior Schedule 13D. Except as specifically amended by this Amendment No. 1, the Prior Schedule 13D is unchanged.

Item 2(a) of the Prior Schedule 13D is hereby amended and restated in its entirety as follows:

This Schedule 13D is being filed jointly by Redmile Group, LLC ("Redmile"), Jeremy C. Green, RedCo I, L.P. ("RedCo I"), Redmile Biopharma Investments II, L.P. ("RBI II"), and Redmile Long Only (collectively with Redmile, Mr. Green, RedCo I and RBI II, the "R eporting Persons"), pursuant to the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as separate persons and not as members of a group. See Exhibit 99.1 to this Schedule 13D for their Joint Filing Ag reement.

(b) Item 2(b) of the Prior Schedule 13D is hereby amended and restated in its entirety as follows:

Redmile:

One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129

Jeremy C. Green: c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001

RedCo I:

c/o Redmile Group, LLC One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129

RBI II:

c/o Redmile Group, LLC One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129

Redmile Long Only: c/o Redmile Group, LLC One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129

(c) Item 2(c) of the Prior Schedule 13D is hereby amended and restated in its entirety as follows:

Redmile: investment manager/adviser to certain private investment vehicles Jeremy C. Green: managing member of Redmile RedCo I: private investment fund RBI II: private investment fund Redmile Long Only: private investment fund

(f) Item 2(f) of the Prior Schedule 13D is hereby amended and restated in its entirety as follows:

Redmile: Delaware Jeremy C. Green: United Kingdom RedCo I: Delaware RBI II: Delaware Redmile Long Only: Cayman Islands

Item 5. Interest in Securities of the Issuer

(a) Item 5(a) of the Prior Schedule 13D is hereby amended and restated in its entirety as follows:

The aggregate amount of shares of Common Stock that may be deemed beneficially owned by the Reporting Persons is comprise d of (i) 441,701 shares of Common Stock held by the Redmile Funds, including the 191,226 shares of Common Stock directly held by RedCo I, the 142,631 shares of Common Stock directly held by RBI II and the 66,855 shares of Common Stock directly held by Redmile Long Only, and (ii) in each case subject to the Beneficial Ownership Blocker, 3,412,843 shares of Common Stock issuable e upon exercise of certain pre-funded warrants to purchase Common Stock (the "Warrants"), including the 156,216 shares of Common Stock issuable upon exercise of the Warrants directly held by RedCo I, the 2,054,155 shares of Common Stock issuable upon exercise of the Warrants directly held by RBI II, and the 827,581 shares of Common Stock issuable upon exercise of the Warrants directly held by Redmile Long Only. Redmile is the investment manager to the Redmile Funds and, in such capacity, exercises voting and investment power over all of the shares held by the Redmile Funds and may be deemed to be the beneficial owner of the ses shares. Jeremy C. Green serves as the managing member of Redmile and also may be deemed to be the beneficial owner of the ses shares. Redmile and Mr. Green each disclaims beneficial ownership of these shares except to the extent of its or his pecunic hese shares. Redmile and Mr. Green each disclaims beneficial ownership of these shares, except to the extent of its or his pecuni ary interest in such shares, if any.

Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of the Warrants, and a holder of a Warrants does not have the right to exercise the Warrants held by such holder, to the extent that after giving effect to such issuance after exercise, th e holder (together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates), would beneficially own in excess of 9.99% (the "Beneficial Ownership Limitation") of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issued upon exercise of the Warrant (the "Beneficial Ownership Blocker"). The Beneficial Ownership Limitation may be changed at a holder's election upon 61 days' no tice to the Issuer.

The 751,223 shares of Common Stock reported as beneficially owned by Redmile and Mr. Green in this Schedule 13D represent 9.99% of the outstanding shares of Common Stock. The 347,442 shares of Common Stock reported as beneficially owned by Red Co I in this Schedule 13D represent 4.7% of the outstanding shares of Common Stock. The 452,153 shares of Common Stock reported as beneficially owned by RBI II in this Schedule 13D represent 6.0% of the outstanding shares of Common Stock. The 376,3 77 shares of Common Stock reported as beneficially owned by Redmile Long Only in this Schedule 13D represent 5.0% of the out standing shares of Common Stock.

For purposes of this Schedule 13D, the percent of class for each Reporting Person, other than RedCo I, was calculated based on sum of: (i) 7,210,235 shares of Common Stock outstanding as of November 6, 2025, as reported by the Issuer in its Form 10-Q for the quarterly period ended September 30, 2025 filed with the SEC on November 12, 2025 (the "Form 10-Q"), plus (ii) 309,522 shares of Common Stock issuable upon exercise of the Warrants directly held by the Redmile Funds, which due to the Beneficial Own ership Limitation is the maximum number of shares that could be issued upon exercise of those Warrants. The percent of class for RedCo I was calculated based on sum of: (i) 7,210,235 shares of Common Stock outstanding as of November 6, 2025, as reported by the Issuer in its Form 10-Q, plus (ii) 156,216 shares of Common Stock issuable upon exercise of the Warrants directly held by RedCo I, which due to the Beneficial Ownership I, imitation is the maximum number of shares that could be issued upon exercise. y RedCo I, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued upon exercise of those Warrants.

(b) Item 5(b) of the Prior Schedule 13D is hereby amended and restated in its entirety as follows:

Redmile:

- (1) Sole Voting Power: 0
- Shared Voting Power: 751,223
- (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 751,223

- Jeremy C. Green: (1) Sole Voting Power: 0
- Shared Voting Power: 751,223
- (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 751,223

RedCo I:

- (1) Sole Voting Power: 0
- Shared Voting Power: 347,442
- Sole Dispositive Power: 0
- (4) Shared Dispositive Power: 347,442

- (1) Sole Voting Power: 0
- Shared Voting Power: 452,153
- Sole Dispositive Power: 0
- (4) Shared Dispositive Power: 452,153

Redmile Long Only:

- (1) Sole Voting Power: 0
- Shared Voting Power: 376,377
- Sole Dispositive Power: 0
- (4) Shared Dispositive Power: 376,377

(e) RedCo I ceased to be a 5% beneficial owner when the Issuer reported the increase in its outstanding Common Stock in its Form 1 0-Q filed on November 12, 2025.

Item 7. Material to be Filed as Exhibits.

Exhibit 99.3: Joint Filing Agreement, dated as of November 14, 2025, by and among Redmile, Jeremy C. Green, RedCo I, RBI II a nd Redmile Long Only.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Redmile Group, LLC

Signature: /s/ Jeremy C. Green Name/Title: **Managing Member**

Date: 11/14/2025

Jeremy C. Green

Signature: /s/ Jeremy C. Green Name/Title: Jeremy C. Green Date: 11/14/2025

RedCo I, L.P.

Signature: /s/ Jeremy C. Green

Managing Member of RedCo I (GP), LLC, general partner of RedCo I, L.P. Name/Title:

Date: 11/14/2025

Redmile Biopharma Investments II, L.P.

Signature: /s/ Jeremy C. Green

Managing Member of Redmile Biopharma Investments II (GP), LLC, general partner of Redmile Biopharma Investments II, L.P. Name/Title:

Date: 11/14/2025

Redmile Strategic Long Only Trading Sub, Ltd.

Signature: /s/ Jeremy C. Green

Managing Member of Redmile Group, LLC, investment manager of Redmile Strategic Long Only Trading Sub, Name/Title:

Date: 11/14/2025

Joint Filing Agreement

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto, the "Schedule 13D") relating to the common stock, \$0.0001 par value per share, of Atara Biotherapeutics, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.

The undersigned further agree that each party hereto is responsible for the timely filing of the Schedule 13D, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has a reason to believe that such information is inaccurate.

It is understood and agreed that a copy of this Joint Filing Agreement shall be attached as an exhibit to the Schedule 13D, filed on behalf of each of the parties hereto.

IN WITNESS WHEREOF, each of the undersigned has executed this Joint Filing Agreement as of the 14th day of November, 2025.

REDMILE GROUP, LLC

/s/ Jeremy C. Green

Name: Jeremy C. Green Title: Managing Member

/s/ Jeremy C. Green

JEREMY C. GREEN

REDCO I, L.P.

BY: REDCO I (GP), LLC, ITS GENERAL PARTNER

BY: REDMILE GROUP, LLC, ITS MANAGING MEMBER

/s/ Jeremy C. Green

Name: Jeremy C. Green Title: Managing Member

REDMILE BIOPHARMA INVESTMENTS II, L.P.

BY: REDMILE BIOPHARMA INVESTMENTS II (GP), LLC, ITS GENERAL PARTNER

/s/ Jeremy C. Green

Name: Jeremy C. Green Title: Managing Member

REDMILE STRATEGIC LONG ONLY TRADING SUB, LTD.

BY: REDMILE GROUP, LLC, ITS INVESTMENT MANAGER

/s/ Jeremy C. Green

Name: Jeremy C. Green
Title: Managing Member